Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Polycystic Ovary Syndrome 10Insulin Resistance 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Prostatic Neoplasms 4Diabetes Mellitus, Type 2 4Pancreatic Neoplasms 3Diabetes Mellitus 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Metabolic Syndrome 2Leukoplakia, Oral 2Leukemia, Myeloid, Chronic-Phase 2Inflammation 2Carotid Intimal Medial Thickness 1 2Breast Neoplasms 2Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Pharmacokinetics of MDV3100 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Meningioma 1Memory Disorders 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Myeloid, Acute 1

Interventions

Magnetic Resonance Spectroscopy 16Hydroxyurea 7Everolimus 7Bevacizumab 7lutetium Lu 177 dotatate 6gallium Ga 68 dotatate 6Radiosurgery 6Proton Therapy 6Specimen Handling 5pembrolizumab 4Surveys and Questionnaires 4Surgical Procedures, Operative 4Radiotherapy 4Imatinib Mesylate 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4aldesleukin 3abemaciclib 3Tranexamic Acid 3Temozolomide 3Sunitinib 3Sodium Chloride 3Radiotherapy, Intensity-Modulated 3Observation 3Nivolumab 3Ga(III)-DOTATOC 390Y-octreotide, DOTA-Tyr(3)- 3vistusertib 2trametinib 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × Pioglitazone × Clear all
NCT01151670 2018-08-01

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Wake Forest University Health Sciences

Phase 1 Completed
18 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Memory Disorders, Meningioma, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡